Lupin announces FDA approval of Solosec
BALTIMORE — Lupin Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years